Therapeutic adherence is the measure of how closely a person’s behavior (taking medication, following a diet, or changing their lifestyle) aligns with the recommendations agreed upon with a healthcare professional.
It is estimated (AIFA data) that poor therapeutic adherence leads to 200,000 deaths annually in Europe, with an overall cost to the healthcare system of 80 billion euros.
Trillio is a continuously connected device designed specifically for seniors and chronic patients, aiding in the correct adherence to a medical prescription.
The entire configuration is transmitted to TRILLIO by the ‘Caregiver’ (the doctor, a family member, the pharmacist…). The Caregiver uses their smartphone, tablet, or computer to set up the prescription plan (with schedules, names of medicines, doses, etc.), which is then automatically transmitted to TRILLIO.
Need
Trillio has been funded by the European Commission through the SME Instrument (Phase 1), receiving a grant of €50,000 for the development of the feasibility study. The study will last for 6 months, starting from May 2018.Developing a feasibility study with the aim of:
Defining the market potential of the product in relation to the target markets.
Defining the regulatory framework.
Outlining additional pipelines for technological development.
Finalizing the project’s business plan.
Defining the most appropriate distribution strategy.
Project
Trillio has been funded by the European Commission through the SME Instrument (Phase 1), receiving a grant of €50,000 for the development of the feasibility study. The study will last for 6 months, starting from May 2018.
idea-re
idea-re supported La Comanda in submitting the funding application, identifying partners for the development of the first pilot projects, and in the development of the feasibility study.